Exited position

George Soros’s Dexcom Inc (DXCM) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Soros Fund ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2010Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares185.00KHighest verified quarter-end share count
Quarters reported14Verified quarters with shares above zero
What happened?

Soros Fund Management first reported Dexcom Inc in Q3 2010. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Soros Fund Management sold the entire position in Q3 2024, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2024
Sold the entire position−166.80K shares · No shares reported at quarter-end
Q2 2024
Bought 233.6% more+116.80K shares · 166.80K shares reported after the change
Filing context

Quarter-end price $113.38 · Estimated holding basis $107.36

Q1 2024
Sold 54.5% of the position−60.00K shares · 50.00K shares remained
Filing context

Quarter-end price $138.70 · Estimated holding basis $93.30

Q4 2023
Sold 40.5% of the position−75.00K shares · 110.00K shares remained
Filing context

Quarter-end price $124.09 · Estimated holding basis $93.30

Q3 2023
New position+185.00K shares · 185.00K shares reported
Filing context

Quarter-end price $93.30 · Estimated holding basis $93.30

Q1 2018
Sold the entire position−3.80K shares · No shares reported at quarter-end

1 unchanged quarter is collapsed by default.

Portfolio importance

How important was Dexcom Inc in Soros Fund Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.4%Q2 2024
Last reported rank#61of 159 reported positions
Peak portfolio weight0.4%Q2 2024
Best historical rank#61Q2 2024
At peak importanceQ2 2024
DXCM
0.4%
Largest holding
5.5%
Cross-investor discovery

Who else owns Dexcom Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Ray DalioBridgewater Associates, LP
DXCM0.1% of reported portfolio
Joel GreenblattGotham Asset Management
DXCM0.0% of reported portfolio
Explore Dexcom Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$84.682026-09-14

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Soros Fund Management LLC’s Form 13F disclosures—not George Soros’s personal brokerage account. George Soros founded the firm; its current CEO and chief investment officer is Dawn Fitzpatrick. Form 13F does not reveal exact trade dates, execution prices or the purpose of an option position.